Trial Profile
A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2020
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms ADAPT
- Sponsors Janssen
- 08 Aug 2019 Status changed from active, no longer recruiting to completed.
- 18 Apr 2019 Planned End Date changed from 1 Jul 2019 to 17 Jul 2019.
- 18 Apr 2019 Planned primary completion date changed from 1 Jul 2019 to 17 Jul 2019.